CODX - Co-Diagnostics, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.0900 |
| Open | 1.1000 |
| Bid | 1.0600 x 800 |
| Ask | 1.1400 x 1200 |
| Day's Range | 1.0850 - 1.1700 |
| 52 Week Range | 0.9750 - 7.1300 |
| Volume | |
| Avg. Volume | 143,793 |
| Market Cap | 32.987M |
| Beta (5Y Monthly) | -0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0200 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
Fair Value
Related Research
Simply Wall St.One Co-Diagnostics, Inc. (NASDAQ:CODX) Broker Just Cut Their Revenue Forecasts By 14%
The latest analyst coverage could presage a bad day for Co-Diagnostics, Inc. ( NASDAQ:CODX ), with the covering analyst...
ZacksCo-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireCo-Diagnostics, Inc. Reports First Quarter 2023 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the quarter ended March 31, 2023.
- PR Newswire
Co-Diagnostics, Inc. to Host Booth at Senior Living Executive Conference in New Orleans, LA
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at Argentum's 2023 Senior Living Executive Conference and Expo, being held May 8-10 in New Orleans, LA.
- PR Newswire
Co-Diagnostics, Inc. Announces First Quarter 2023 Earnings Release Date and Webcast
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2023 results on Thursday, May 11, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive Off
- PR Newswire
Co-Diagnostics, Inc. to Host Booth at 67th Annual CARPHA Conference April 27-29
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the Caribbean Public Health Agency (CARPHA) 67th Annual Health Research Conference, being held in-person April 27-29, 2023, in the Bahamas.
- PR Newswire
Co-Diagnostics, Inc. to Host Booth at ECCMID 2023 April 15-18 in Copenhagen, Denmark
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 15-18, 2023, in Copenhagen, Denmark.
- Simply Wall St.
Co-Diagnostics (NASDAQ:CODX shareholders incur further losses as stock declines 45% this week, taking three-year losses to 83%
As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So take a...
- PR Newswire
Co-Diagnostics, Inc. to CEO to Deliver Keynote Address at 2023 MarketsandMarkets Conference in London, England
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company CEO will deliver the keynote address at the 4th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2023, in London, England, where the Company will also be hosting a booth.
Insider MonkeyCo-Diagnostics, Inc. (NASDAQ:CODX) Q4 2022 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good afternoon, and welcome to the Co-Diagnostics, Inc. Fourth Quarter and Full Year 2022 Earnings Results Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note that this event is […]
- PR Newswire
Co-Diagnostics, Inc. to Host Booth at 10th Gene Quantification Event in Munich, Germany, March 20-22
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 10th Gene Quantification Event held March 20-24 at the Technical University of Munich. Dr. Carl Wittwer, Chair of the Company's Scientific Advisory Board (SAB) will also be presenting at the event.
- Thomson Reuters StreetEvents
Q4 2022 Co-Diagnostics Inc Earnings Call
Q4 2022 Co-Diagnostics Inc Earnings Call
ZacksCo-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022.
- PR Newswire
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2022 results on Thursday, March 16, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors.
- PR Newswire
Co-Diagnostics, Inc. to Present and Host Booth at TRI-CON in San Diego, CA, March 6-8
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 30th Molecular and Precision Med TRI-CON ("TRI-CON"), held virtually and in person March 6-8, 2023, in San Diego, CA.
- PR Newswire
Co-Diagnostics, Inc. to Host Booth at 89th Annual AMCA Conference in Reno, NV on Feb 28-March 3
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming 89th annual American Mosquito Control Association (AMCA) conference on February 28-March 3 in Reno, Nevada.
PR NewswireCo-Diagnostics, Inc. Initiates Clinical Evaluations for its At-Home and Point-of-Care Co-Dx PCR Home™ Platform
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has commenced clinical evaluations for its at-home and point-of-care Co-Dx PCR Home™ platform and initial COVID-19 test, consisting of the clinical trials and analytical studies that are expected to support submissions to the United States FDA and other regulatory bodies.
PR NewswireCo-Diagnostics, Inc. to Host Booth at Medlab Middle East 2023 in Dubai on February 6-9
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Medlab Middle East 2023 trade show held February 6-9 at the Dubai World Trade Centre.
PR NewswireCo-Diagnostics, Inc. Commemorates Third Anniversary of the Completion of its First COVID-19 Test Design
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, yesterday commemorated the third anniversary of the completion of the principal design work of a Co-Primers™ PCR test for what was, on January 23, 2020, still known as 2019-nCoV, or the novel coronavirus.
- PR Newswire
Co-Diagnostics, Inc. to Host Booth at CES 2023 January 5-8
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the 2023 Consumer Electronics Show (CES) this year from January 5-8 in Las Vegas, Nevada.
- Simply Wall St.
Co-Diagnostics, Inc. (NASDAQ:CODX) Analysts Are More Bearish Than They Used To Be
Market forces rained on the parade of Co-Diagnostics, Inc. ( NASDAQ:CODX ) shareholders today, when the analysts...
- PR Newswire
Co-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting on December 1, 2022, at the Piper Sandler 34th Annual Healthcare Conference, held November 29-December 31, 2022, in New York City, New York.
- Simply Wall St.
Co-Diagnostics Third Quarter 2022 Earnings: Misses Expectations
Co-Diagnostics ( NASDAQ:CODX ) Third Quarter 2022 Results Key Financial Results Revenue: US$5.09m (down 83% from 3Q...
- PR Newswire
Co-Diagnostics, Inc. to Host Booth at MEDICA 2022 Trade Fair in Düsseldorf, Germany
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the MEDICA 2022 trade fair in Düsseldorf, Germany from 15-17 November.